26 October 2012

Equity Focus

Key Sector Data

Average PER (x)	16.1
Average PBV (x)	1.7
Average PEV (x)	1.1
Average VNB (x)	1.8
Average Dividend Yield (%)	0.9
Sector Market cap (HK\$bn)	1,479
Average 30-day avg vol (HK\$mn)	1,871
Sector Weighting in MSCI China	~ 8%

Source: Company, Bloomberg, ABCI Securities

Sector Premium composition in 2011 (%)

Life	60.6
Health	4.8
Personal Accident	2.3
Property & Casualty	32.2

Source: Companies, CIRC

Sector performance (%)

	Absolute	Relative*
1-mth	4.34	(2.51)
3-mth	(3.73)	(18.00)
6-mth	(2.71)	(3.32)

Source: Bloomberg
*Relative to MSCI China

1 year relative performance vs MSCI China



Source: Bloomberg

Analyst:

Francis Chan Tel: (852) 2147 8311

Email: francischan@abci.com.hk

China Insurance Sector - Overweight Life & Health Insurance Industry

Improving premiums sales implying further recovery

China Insurance sector reported premiums figures for Sep 2012 lately. Four insurers reported sequentially better life and P&C premium growth. Together with a recovery of A-share markets and QE3 announced in US, the sector traded up 12.6% since early Sep. Currently, China insurers have further recovered in valuation, trading at an average of 1.13x 2013E PEV and 1.8x 2012E VNB. We expect the sector to outperform the market for the rest of 2012. We favor China Life and China Pacific currently, mainly due to their substantial NBM improvement in 1H12.

China Life's downtrend reversed. Sep life premiums reached Rmb263.1bn, flattish YoY (down 3.2% YoY year to Aug) during the period. Monthly Sep premiums recorded Rmb33.8bn, up 24.0% YoY, reversing from down 10.0% YoY for the month of Jul. China Life continues to benefit from the good sales of Kang Ning CI and the new direct sales products.

Ping An Life with slight sequential improvements. Sep life premiums reached Rmb100.9bn, up 7.4% YoY (up 6.6% YoY year to Aug) during the period. P&C premium was reported at Rmb73.9bn, up 20.0% YoY (flattish MoM). We consider this a slightly better result sequentially.

China Pacific holding up well. Sep life premiums reached Rmb74.9bn, flattish YoY during the period. P&C premium was reported at Rmb51.9bn, up 11.1% YoY (up 10.5% YoY year to Aug). In our view, Life premiums are stabilizing for China Pacific.

Taiping life much better off. Sep life premiums reached Rmb26.7bn, up 10.0% YoY (up 7.0% YoY year to Aug) during the period. Meanwhile, the product mix further improves, with 82.1% of total premium sales as regular. This is compared to 79.9% in 2011. As such, we expect its new business margins to hold up well in 2H12 (1H12 -31.9%, 2011 – 26.5%).

Maintain OVERWEIGHT; Top picks: China Life & China Pacific. We are optimistic on the development of health products. As such, we reiterate our Overweight rating on China Insurance. Our top picks are China Life and China Pacific. Our SELL is Ping An. Also, we have a HOLD rating on New China Life and a BUY rating on China Taiping.

Risk factors: worse-than-expected underwriting and investmen performance, tighter-than-expected regulations for the sector

Sector Valuation Summary

Companies	Code	Price	MCap	ABCI	TP	PER	PBV	PEV	VNB	Yield
		(HK\$)	(HK\$ bn)	Rec.	(HK\$)	2013E	2013E	2013E	2013E	2013E
China Life	2628 hk	22.90	647	BUY	26.45	17.5	2.1	1.3	6.1	1.8%
Ping An	2318 hk	63.35	501	SELL	58.04	14.0	1.8	1.2	4.9	1.1%
China Pacific	2601 hk	25.05	227	BUY	27.93	20.0	1.7	1.2	0.0	1.7%
New China Life	1336 hk	25.65	80	HOLD	24.85	15.0	1.5	0.9	(1.1)	0.0%
China Taiping	0966 hk	13.36	23	BUY	13.42	13.8	1.3	1.0	(0.9)	0.0%
Sector Average						16.1	1.7	1.1	1.8	0.9%

Source: Company, Bloomberg, ABCI Securities



Disclosures

Analyst Certification

I, Chan Wing Fu (Francis Chan), being the person primarily responsible for the content of this research report, in whole or in part, hereby certify that all of the views expressed in this report accurately reflect my personal view about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. I and/or my associates have no financial interests in relation to the listed company (ies) covered in this report, and I and/or my associates do not serve as officer(s) of the listed company (ies) covered in this report.

Definition of equity rating

Rating	Definition
Buy	Stock return ≥ Market return rate
Hold	Market return $-6\% \le \text{Stock}$ return $<$ Market return rate
Sell	Stock return < Market return − 6%

Stock return is defined as the expected % change of share price plus gross dividend yield over the next 12 months

Market return: 5-year average market return rate from 2007-2011

Time horizon of share price target: 12-month

Definition of share price risk

Rating	Definition
Very high	2.6 ≤180 day volatility/180 day benchmark index volatility
High	$1.5 \le 180$ day volatility/180 day benchmark index volatility < 2.6
Medium	1.0 ≤180 day volatility/180 day benchmark index volatility < 1.5
Low	180 day volatility/180 day benchmark index volatility < 1.0

We measure share price risk by its volatility relative to volatility of benchmark index. Benchmark index: Hang Seng Index.

Volatility is calculated from the standard deviation of day to day logarithmic historic price change. The 180-day price volatility equals the annualized standard deviation of the relative price change for the 180 most recent trading days closing price.

Disclosures of Interests

ABCI Securities Company Limited and/or its affiliates, within the past 12 months, have received compensation and/or within the next 3 months seek to obtain compensation for investment banking services from one of the companies mentioned in the report.

Disclaimers

This report is for our clients only and is for distribution only under such circumstances as may be permitted by applicable law. It has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient. It is published solely for informational purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. No representation or warranty, either expresses or implied, is provided in relation to the accuracy, completeness or reliability of the information contained herein. This report should not be regarded by recipients as a substitute for the exercise of their own judgment. Any opinions expressed in this report are subject to change without notice and may differ or be contrary to opinions expressed by other business areas as a result of using different assumptions and criteria. The analysis contained herein is based on numerous assumptions. Different assumptions could result in materially different results. The analyst(s) responsible for the preparation of this report may interact with trading desk personnel, sales personnel and other constituencies for the purpose of gathering, synthesizing and interpreting market information. ABCI Securities Company Limited is under no obligation to update or keep current the information contained herein. ABCI Securities Company Limited relies on information barriers to control the flow of information contained in one or more areas within ABCI Securities Company Limited, into other areas, units, groups or affiliates of ABCI Securities Company Limited. The compensation of the analyst



who prepared this report is determined exclusively by research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues, however, compensation may relate to the revenues of ABCI Securities Company Limited as a whole, of which investment banking, sales and trading are a part. The securities described herein may not be eligible for sale in all jurisdictions or to certain categories of investors. The price and value of the investments referred to in this research and the income from them may fluctuate. Past performance is not necessarily indicative of future results. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument mentioned in this report. For investment advice, trade execution or other enquiries, clients should contact their local sales representative. Neither ABCI Securities Company Limited nor any of its affiliates, directors, employees or agents accepts any liability for any loss or damage arising out of the use of all or any part of this report. Additional information will be made available upon request.

Copyright 2012 ABCI Securities Company Limited

No part of this material may be (i) copied, photocopied or duplicated in any form by any means or (ii) redistributed without the prior written consent of ABCI Securities Company Limited.

Office address: ABCI Securities Company Limited, 13/F Fairmont House, 8 Cotton Tree Drive, Central, Hong Kong.
Tel: (852) 2868 2183